Plaque Psoriasis

Immunology
55
Pipeline Programs
27
Companies
50
Clinical Trials
7 recruiting
7
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
1
16
0
20
12
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
6100%
+ 45 programs with unclassified modality

On Market (7)

Approved therapies currently available

U
ACITRETINApproved
acitretin
Unknown Company
Retinoid [EPC]oral2015
UP
BIMZELXApproved
bimekizumab
UCB Pharma
injection2023
Novartis
COSENTYXApproved
secukinumab
Novartis
Interleukin-17A Antagonist [EPC]injection2023
U
ENBRELApproved
etanercept
Unknown Company
Tumor Necrosis Factor Blocker [EPC]subcutaneous1998
Amgen
OTEZLAApproved
apremilast
Amgen
Phosphodiesterase 4 Inhibitor [EPC]oral2014
Amgen
OTEZLA XRApproved
apremilast
Amgen
oral2025
GSK
SORIATANEApproved
acitretin
GSK
oral1996

Competitive Landscape

27 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
4 programs
3
1
etanerceptPhase 41 trial
ABP 654Phase 31 trial
ApremilastPhase 31 trial
ApremilastPhase 31 trial
Active Trials
NCT04607980Completed563Est. Jun 2022
NCT03930186Completed152Est. Sep 2020
NCT01194219Completed844Est. Nov 2016
+1 more trials
Astellas
AstellasChina - Shenyang
2 programs
1
alefaceptPhase 45 trials
Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.Eā„¢) ProgramN/A1 trial
Active Trials
NCT00371774Completed426Est. May 2008
NCT01433770Withdrawn0Est. Oct 2014
NCT01226420Terminated6Est. Aug 2012
+3 more trials
UP
UCB PharmaBelgium - Brussels
2 programs
1
BimekizumabPhase 4Monoclonal Antibody1 trial
Certolizumab pegolN/A1 trial
Active Trials
NCT04053881Completed412Est. Dec 2022
NCT06336343Recruiting60Est. Mar 2026
Novartis
NovartisBASEL, Switzerland
2 programs
1
COSENTYX(Secukinumab)Phase 4Monoclonal Antibody1 trial
PEST Screening groupN/A1 trial
Active Trials
NCT06382051Recruiting502Est. Aug 2026
NCT03055494Completed102Est. Feb 2019
GSK
GSKLONDON, United Kingdom
1 program
1
AcitretinPhase 41 trial
Active Trials
NCT00832364Withdrawn0Est. Apr 2010
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
7 programs
1
6
210 mg brodalumabPhase 3Monoclonal Antibody1 trial
IDP-118 LotionPhase 31 trial
IDP-118 LotionPhase 31 trial
IDP-118 LotionPhase 31 trial
IDP-122 LotionPhase 31 trial
+2 more programs
Active Trials
NCT02045277CompletedEst. Nov 2014
NCT01708629TerminatedEst. Oct 2015
NCT02462070CompletedEst. Dec 2016
+4 more trials
Alumis
AlumisSOUTH SAN FRANCISCO, CA
5 programs
2
3
ESK-001Phase 31 trial
ESK-001Phase 31 trial
Open-Label ESK-001Phase 31 trial
ESK-001Phase 21 trial
ESK-001Phase 21 trial
Active Trials
NCT05739435Active Not Recruiting165Est. Dec 2026
NCT05600036Completed228Est. Jul 2023
NCT06586112Active Not Recruiting840Est. Dec 2025
+2 more trials
Abbott
AbbottABBOTT PARK, IL
2 programs
2
ABT-874Phase 31 trial
Adalimumab every other weekPhase 31 trial
Active Trials
NCT00691964Completed347Est. Mar 2009
NCT00927069Completed85Est. Dec 2008
Alvotech
AlvotechLUXEMBOURG, Luxembourg
2 programs
2
AdalimumabPhase 3Monoclonal Antibody1 trial
Adalimumab originatorPhase 31 trial
Active Trials
NCT03849404Completed413Est. Jul 2020
NCT04453137Completed567Est. Nov 2021
Coherus Oncology
Coherus OncologyCA - Redwood City
2 programs
2
CHS-1420Phase 31 trial
EtanerceptPhase 31 trial
Active Trials
NCT02489227Completed545Est. Mar 2017
NCT02134210Completed521Est. May 2016
Celltrion
CelltrionKorea - Incheon
1 program
1
CT-P55Phase 31 trial
Active Trials
NCT06630559Active Not Recruiting153Est. Oct 2026
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
RisankizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04102007Completed244Est. Nov 2022
Akros Pharma
Akros PharmaNJ - Princeton
3 programs
1
2
JTE-051Phase 21 trial
JTE-451 TabletsPhase 21 trial
JTE-451Phase 11 trial
Active Trials
NCT03018509Completed47Est. Jun 2017
NCT03358290Terminated13Est. Oct 2018
NCT03832738Completed152Est. Mar 2020
Oruka Therapeutics
Oruka TherapeuticsMA - Waltham
3 programs
3
ORKA-001Phase 21 trial
ORKA-001Phase 21 trial
ORKA-001 Induction DosePhase 21 trial
Active Trials
NCT07290569RecruitingEst. Dec 2028
NCT07449702RecruitingEst. Jan 2029
NCT07090330RecruitingEst. May 2027
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
2
DC-806Phase 21 trial
MirikizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05896527Completed229Est. Mar 2024
NCT02899988Completed205Est. May 2019
Affibody
AffibodySweden - Solna
1 program
1
ABY-035Phase 21 trial
Active Trials
NCT03591887Completed108Est. Dec 2021
Accro Bioscience
Accro BioscienceChina - Suzhou
1 program
1
AC-201Phase 21 trial
Active Trials
NCT06972888CompletedEst. Apr 2025
Aurigene
AurigeneIndia - Bangalore
1 program
1
AUR101Phase 21 trial
Active Trials
NCT04855721Completed141Est. Dec 2022
InnoCare
InnoCareChina - Beijing
1 program
1
ICP-332 TabletsPhase 21 trial
Active Trials
NCT07251998Recruiting172Est. May 2027
CT
1 program
1
TQH3906 capsulesPhase 21 trial
Active Trials
NCT06542614CompletedEst. Dec 2025
Zai Lab
Zai LabCA - South SF
1 program
1
ZL-1102 1% w/w gel BID for 16 weeksPhase 21 trial
Active Trials
NCT06380907Recruiting250Est. Mar 2026
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
1
CS32582 capsule(low dose) or matched placeboPhase 1/21 trial
Active Trials
NCT07129382RecruitingEst. Sep 2027
Galapagos
Galapagos2800 MECHELEN, Belgium
1 program
1
GLPG3667Phase 11 trial
Active Trials
NCT04594928Completed30Est. May 2021
Pfizer
PfizerNEW YORK, NY
1 program
1
ILV-095 300 mg in a 4 to 1 ratioPhase 11 trial
Active Trials
NCT01010542Terminated39Est. May 2011
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK-0873 PatchPhase 11 trial
Active Trials
NCT01140061Completed42Est. Mar 2011
Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
1
SOR007 Ointment 2.0%Phase 11 trial
Active Trials
NCT03004339CompletedEst. Feb 2017
NKGEN Biotech
NKGEN BiotechCA - Santa Ana
1 program
1
Study Product: SNK01Phase 11 trial
Active Trials
NCT03894579Completed9Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
UCB PharmaBimekizumab
NovartisSecukinumab
GSKAcitretin
Amgenetanercept
Astellasalefacept
Astellasalefacept
Astellasalefacept
CelltrionCT-P55
AlumisOpen-Label ESK-001
AlumisESK-001
AlumisESK-001
AmgenABP 654
AlvotechAdalimumab originator
AbbVieRisankizumab
AmgenApremilast

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 10,423 patients across 50 trials

Bimekizumab in Plaque Psoriasis

Start: Jun 2024Est. completion: Mar 202660 patients
Phase 4Recruiting

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

Start: Apr 2017Est. completion: Feb 2019102 patients
Phase 4Completed

Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

Start: Oct 2009Est. completion: Apr 20100
Phase 4Withdrawn

The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab

Start: Feb 2009Est. completion: Feb 201010 patients
Phase 4Completed

Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy

Start: Feb 2008Est. completion: Dec 20081 patients
Phase 4Terminated

Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects

Start: Oct 2007Est. completion: Dec 200998 patients
Phase 4Completed

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Start: Jul 2007Est. completion: Jul 200843 patients
Phase 4Completed

A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis

Start: May 2025Est. completion: Oct 2026153 patients
Phase 3Active Not Recruiting
NCT06846541AlumisOpen-Label ESK-001

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Start: Jan 2025Est. completion: Nov 20281,680 patients
Phase 3Active Not Recruiting

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

Start: Aug 2024Est. completion: Dec 2025840 patients
Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

Start: Jul 2024Est. completion: Dec 2025840 patients
Phase 3Active Not Recruiting

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Start: Nov 2020Est. completion: Jun 2022563 patients
Phase 3Completed
NCT04453137AlvotechAdalimumab originator

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Start: Jun 2020Est. completion: Nov 2021567 patients
Phase 3Completed
NCT04102007AbbVieRisankizumab

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

Start: Nov 2019Est. completion: Nov 2022244 patients
Phase 3Completed

A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

Start: Jun 2019Est. completion: Sep 2020152 patients
Phase 3Completed

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Start: Feb 2019Est. completion: Jul 2020413 patients
Phase 3Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Start: Nov 2015Est. completion: May 2017
Phase 3Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Start: Nov 2015Est. completion: Mar 2017
Phase 3Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Start: Aug 2015Est. completion: Nov 2016
Phase 3Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Start: Aug 2015Est. completion: Dec 2016
Phase 3Completed

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Start: Aug 2015Est. completion: Apr 2017
Phase 3Completed

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

Start: Aug 2015Est. completion: Mar 2017545 patients
Phase 3Completed

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

Start: Jun 2014Est. completion: May 2016521 patients
Phase 3Completed
NCT01708629Bausch Health210 mg brodalumab

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Start: Sep 2012Est. completion: Oct 2015
Phase 3Terminated

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

Start: Sep 2010Est. completion: Nov 2016844 patients
Phase 3Completed

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Start: May 2008Est. completion: Mar 2009347 patients
Phase 3Completed
NCT00927069AbbottAdalimumab every other week

Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept

Start: Mar 2007Est. completion: Dec 200885 patients
Phase 3Completed

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

Start: Jul 2003Est. completion: Apr 200478 patients
Phase 3Completed

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Start: Feb 2026Est. completion: Jan 2029
Phase 2Recruiting
NCT07251998InnoCareICP-332 Tablets

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

Start: Dec 2025Est. completion: May 2027172 patients
Phase 2Recruiting

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Start: Dec 2025Est. completion: Dec 2028
Phase 2Recruiting
NCT07090330Oruka TherapeuticsORKA-001 Induction Dose

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

Start: Jul 2025Est. completion: May 2027
Phase 2Recruiting

Treatment of Moderate to Severe Plaque Psoriasis

Start: Aug 2024Est. completion: Dec 2025
Phase 2Completed
NCT06380907Zai LabZL-1102 1% w/w gel BID for 16 weeks

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

Start: May 2024Est. completion: Mar 2026250 patients
Phase 2Recruiting

A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis

Start: Apr 2024Est. completion: Apr 2025
Phase 2Completed

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

Start: May 2023Est. completion: Mar 2024229 patients
Phase 2Completed

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Start: Jan 2023Est. completion: Dec 2026165 patients
Phase 2Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Start: Sep 2022Est. completion: Jul 2023228 patients
Phase 2Completed

A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)

Start: May 2021Est. completion: Dec 2022141 patients
Phase 2Completed

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

Start: Jan 2019Est. completion: Mar 2020152 patients
Phase 2Completed

A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

Start: Mar 2018Est. completion: Dec 2021108 patients
Phase 2Completed

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

Start: Nov 2017Est. completion: Oct 201813 patients
Phase 2Terminated

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Start: Sep 2016Est. completion: May 2019205 patients
Phase 2Completed

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Start: Feb 2014Est. completion: Nov 2014
Phase 2Completed

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

Start: Oct 2010Est. completion: Aug 20126 patients
Phase 2Terminated

Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis

Start: Apr 2009Est. completion: Feb 201230 patients
Phase 2Completed

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

Start: Feb 2008Est. completion: Feb 2011323 patients
Phase 2Completed

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Start: Sep 2003Est. completion: Mar 2005185 patients
Phase 2Completed
NCT07129382Chipscreen BiosciencesCS32582 capsule(low dose) or matched placebo

A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

Start: Sep 2025Est. completion: Sep 2027
Phase 1/2Recruiting

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Start: Oct 2020Est. completion: May 202130 patients
Phase 1Completed

Related Jobs in Immunology

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

20 late-stage (Phase 3) programs — potential near-term approvals
7 actively recruiting trials targeting 10,423 patients
27 companies competing in this space